Department of Hematology, Faculty of Medicine, Pamukkale University, Denizli, Turkey
Department of Hematology, Recep Tayyip Erdogan University Traning and Research Hospital, Rize, Turkey
Turk J Med Sci. 2021 Aug 30;51(4):2112-2119. doi: 10.3906/sag-2101-406.
BACKGROUND/AIM: The aim of the study was to evaluate the effect of Controlling Nutritional Status (CONUT) score on the prognosis in patients with diffuse large B-cell lymphoma (DLBCL).
The present study was a retrospective study. The CONUT score was calculated based on serum albumin, total cholesterol and lymphocyte levels. This study included a total of 266 patients, 131 (49.2%) were female and 135 (50.8%) were male. The median follow-up period was 51 months (range: 1–190).
The median age was 64 years. The cut off CONUT was 1.5. There was a significant difference between patients with high (≥ 2) or low (< 2) CONUT scores in terms of overall survival (OS) and progression-free survival (PFS). The 5-year OS and PFS in patients with high CONUT score was 52.1% and 49.7%. The 5-year OS and PFS in patients with low CONUT score was 79.8% and 75.6% (p < 0.001). In the multivariate analysis for OS, age ≥ 65 years (HR = 1.80, p = 0.028), Eastern Cooperative Oncology Group (ECOG) > 1 (HR = 2.04, p = 0.006), stage IIIA–IVB disease (HR = 2.75, p = 0.001) and the CONUT score (HR = 1.15, p = 0.003) were found statistically significant. In the multivariate analysis for PFS, age ≥ 65 years (HR = 2.02, p = 0.007), stage IIIA–IVB disease (HR = 2.42, p = 0.002) and the CONUT score (HR = 1.19, p = 0.001) were found to be significant parameters.
High CONUT score reduces OS and PFS in DLBCL. CONUT score is an independent, strong prognostic index in patients with DLBCL.
背景/目的：本研究旨在评估控制营养状态（CONUT）评分对弥漫性大 B 细胞淋巴瘤（DLBCL）患者预后的影响。
本研究为回顾性研究。根据血清白蛋白、总胆固醇和淋巴细胞水平计算 CONUT 评分。本研究共纳入 266 例患者，其中 131 例（49.2%）为女性，135 例（50.8%）为男性。中位随访时间为 51 个月（范围：1~190）。
中位年龄为 64 岁。截断值 CONUT 为 1.5。在总体生存（OS）和无进展生存（PFS）方面，高（≥2）或低（<2）CONUT 评分患者之间存在显著差异。高 CONUT 评分患者的 5 年 OS 和 PFS 分别为 52.1%和 49.7%，低 CONUT 评分患者的 5 年 OS 和 PFS 分别为 79.8%和 75.6%（p<0.001）。在 OS 的多变量分析中，年龄≥65 岁（HR=1.80，p=0.028）、东部肿瘤协作组（ECOG）>1（HR=2.04，p=0.006）、III 期-IVB 期疾病（HR=2.75，p=0.001）和 CONUT 评分（HR=1.15，p=0.003）均有统计学意义。在 PFS 的多变量分析中，年龄≥65 岁（HR=2.02，p=0.007）、III 期-IVB 期疾病（HR=2.42，p=0.002）和 CONUT 评分（HR=1.19，p=0.001）是显著的参数。
高 CONUT 评分降低 DLBCL 的 OS 和 PFS。CONUT 评分是 DLBCL 患者独立的、强有力的预后指标。
